• Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock
Investing

Higher rates may not be bad for biotech stocks: find out more

by September 22, 2026
written by September 22, 2026

Wall Street’s prevailing narrative suggests that monetary tightening and higher benchmark interest rates pose an insurmountable headwind for biotech stocks.

However, Mizuho’s senior analyst Jared Holz argues that recent Fed hike carries minimal structural significance for the sector.

Speaking recently with CNBC, Holz emphasized that markets routinely overstate the direct impact of monetary policy on biotech performance.

He views the widespread belief that elevated rates naturally stifle drug development valuation as a psychological misinterpretation rather than a fundamental reality urging investors to look beyond macro rate movements when evaluating industry health.

Interest rates and biotech stocks: what historical data tells us

According to Jared Holz, market data from the past two decades suggests there is no “meaningful” statistical correlation between interest rates and biotech stocks’ performance.

Wall Street’s concerns stem from the unique market conditions of the COVID pandemic era, when near-zero interest rates coincided with a massive surge in healthcare valuations.

Investors came to treat that rare confluence as a “universal rule” rather than an isolated historical event.

When removing that atypical anomaly from the two-decade chart, the relationship between rates and biotech stocks effectively dissolves.

The recent sector weakness reflects self-fulfilling investor perception rather than true fundamental deterioration, the Mizuho analyst noted.

What really determines biotech stocks’ performance

Holz remains convinced that corporate execution – not interest rates – and portfolio diversification are dictating sector winners.

For example, Novo Nordisk shares face headwinds, with shares down about 15% this year, largely because markets view Eli Lilly as the early winner of the obesity drug boom.

Outside of its flagship Wegovy and Cagrisema pipeline, NVO must showcase broader therapeutic scope through aggressive business development.

While Novo’s attempt to acquire Metsera failed after being outbid by Pfizer, strategic deals outside the core weight-loss category could reshape its trajectory.

Investors are increasingly looking beyond single-theme narratives, placing higher value on active dealmaking and pipeline diversification over weight-loss speculation.

Shifting focus toward pragmatic business development

Market leadership across big pharma is actively pivoting away from crowded mega-trends toward strategic deal execution.

While high-flying obesity pure-plays have stumbled, diversified giants like Merck have actually rallied about 40% year-to-date following a series of targeted business development transactions.

By completing five strategic deals over the past year, Merck has successfully diversified its topline exposure away from its Keytruda concentration.

Conversely, Lilly’s smaller transactions have yet to meaningfully boost topline sales – and Novo’s operational missteps have drawn skepticism.

Ultimately, sustained revenue growth and disciplined M&A remain far more consequential drivers for biotechnology and pharmaceutical returns than Federal Reserve rate trajectories.

In short, for investors watching biotech stocks, the takeaway is straightforward: rather than fixating on macro policy, long-term performance hinges on clinical milestone execution and disciplined capital allocation.

The post Higher rates may not be bad for biotech stocks: find out more appeared first on Invezz

0 comment
0
FacebookTwitterPinterestEmail

previous post
Alibaba stock forms a bullish pattern as it unveils new advanced AI chip
next post
AutoZone stock has fallen 31% but can earnings break the bearish narrative?

related articles

The complicated business of betting on Big Tech’s...

November 21, 2026

FT finds Alice Huang linked to chip network...

November 21, 2026

Is Nvidia’s Colette Kress standing on a glass...

November 21, 2026

Will Jensen Huang’s ouster push founders to secure...

November 21, 2026

Michael Burry takes profits on Nvidia puts as...

November 20, 2026

Why Intel shares are falling over 5% on...

November 20, 2026

PayPal stock falls 4% as leadership shake-up tests...

November 20, 2026

Evening digest: Anthropic slides after record debut, Bitcoin...

November 20, 2026

Why Broadcom shares are down over 11% on...

November 20, 2026

Why CoreWeave and Nebius stocks are falling on...

November 20, 2026
Enter Your Information Below To Receive Free Trading Ideas, Latest News, And Articles.


Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Latest News

  • Why are Micron and SK Hynix stocks struggling today? It’s the CXMT threat again

    September 3, 2026
  • SpaceX stock slips below IPO price: is it time to sell?

    July 15, 2026
  • SoundHound stock breaks key support as short interest surges: Is a squeeze coming?

    October 9, 2026
  • Why is Microsoft stock up 2% on Wednesday?

    September 30, 2026
  • Nvidia stock outlook: Can shares recover after Jensen Huang’s exit?

    November 13, 2026

Popular Posts

  • 1

    Why SpaceX stock is down around 3% on Tuesday

    September 15, 2026
  • 2

    Micron stock falls 4%, why this analyst sees 40% upside for the stock?

    September 28, 2026
  • 3

    Evening digest: US jobs cool, gold falls as Treasury yields rise

    October 2, 2026
  • 4

    Nike stock sinks after earnings as its comeback plan turns into more layoffs

    October 2, 2026
  • 5

    Dow rises 260 points as weak jobs data lifts US stocks

    October 2, 2026

Categories

  • Editor's Pick (711)
  • Investing (2,694)
  • Stock (90)

Latest Posts

  • Top US stocks to watch this week: Cisco, Applied Materials, Rocket Lab

    November 9, 2026
  • Nasdaq futures skyrocket 650 points: 5 things to know before Wall Street opens

    June 25, 2026
  • Why Z.ai shares sank over 10% as Chinese OpenAI rival seeks another $5 billion

    September 14, 2026

Recent Posts

  • Here’s how long it will take for quantum computing to become a reality

    October 21, 2026
  • Nvidia, SanDisk, AMD stocks rebound: is AI panic trade already cracking

    September 16, 2026
  • Why PCE inflation data is not an all clear for US stocks

    September 30, 2026

Editor’s Pick

  • Insiders are buying these 3 stocks: should you too?

    October 28, 2026
  • TeraWulf stock surges as Anthropic signs $19B AI data center lease

    July 6, 2026
  • Josh Brown says these 3 cybersecurity stocks remain attractive

    September 23, 2026
  • About us
  • Contacts
  • Privacy Policy
  • Terms & Conditions

Disclaimer: moneyrisetoday.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2025 moneyrisetoday.com | All Rights Reserved

Money Rise Today – Investing and Stock News
  • Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock